A qualitative study of the adoption of buprenorphine for opioid addiction treatment

Carla A. Green, Dennis McCarty, Jennifer Mertens, Frances L. Lynch, Anadam Hilde, Alison Firemark, Constance M. Weisner, David Pating, Bradley M. Anderson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Qualified physicians may prescribe buprenorphine to treat opioid dependence, but medication use remains controversial. We examined adoption of buprenorphine in two not-for-profit integrated health plans, over time, completing 101 semi-structured interviews with clinicians and clinician-administrators from primary and specialty care. Transcripts were reviewed, coded, and analyzed. A strong leader championing the new treatment was critical for adoption in both health plans. Once clinicians began using buprenorphine, patients' and other clinicians' experiences affected decisions more than did the champion. With experience, protocols developed to manage unsuccessful patients and changed to support maintenance rather than detoxification. Diffusion outside addiction and mental health settings was nonexistent; primary care clinicians cited scope-of-practice issues and referred patients to specialty care. With greater diffusion came questions about long-term use and safety. Recognizing how implementation processes develop may suggest where, when, and how to best expend resources to increase adoption of such treatments.

Original languageEnglish (US)
Pages (from-to)390-401
Number of pages12
JournalJournal of Substance Abuse Treatment
Volume46
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Buprenorphine
Opioid Analgesics
Primary Health Care
Health
Administrative Personnel
Mental Health
Therapeutics
Maintenance
Interviews
Physicians
Safety

Keywords

  • Buprenorphine
  • Diffusion of technology
  • Implementation research
  • Medication adoption
  • Opioid addiction
  • Qualitative research

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Phychiatric Mental Health
  • Medicine (miscellaneous)

Cite this

A qualitative study of the adoption of buprenorphine for opioid addiction treatment. / Green, Carla A.; McCarty, Dennis; Mertens, Jennifer; Lynch, Frances L.; Hilde, Anadam; Firemark, Alison; Weisner, Constance M.; Pating, David; Anderson, Bradley M.

In: Journal of Substance Abuse Treatment, Vol. 46, No. 3, 03.2014, p. 390-401.

Research output: Contribution to journalArticle

Green, CA, McCarty, D, Mertens, J, Lynch, FL, Hilde, A, Firemark, A, Weisner, CM, Pating, D & Anderson, BM 2014, 'A qualitative study of the adoption of buprenorphine for opioid addiction treatment', Journal of Substance Abuse Treatment, vol. 46, no. 3, pp. 390-401. https://doi.org/10.1016/j.jsat.2013.09.002
Green, Carla A. ; McCarty, Dennis ; Mertens, Jennifer ; Lynch, Frances L. ; Hilde, Anadam ; Firemark, Alison ; Weisner, Constance M. ; Pating, David ; Anderson, Bradley M. / A qualitative study of the adoption of buprenorphine for opioid addiction treatment. In: Journal of Substance Abuse Treatment. 2014 ; Vol. 46, No. 3. pp. 390-401.
@article{4364685b6ba64e45a9963fea117048b3,
title = "A qualitative study of the adoption of buprenorphine for opioid addiction treatment",
abstract = "Qualified physicians may prescribe buprenorphine to treat opioid dependence, but medication use remains controversial. We examined adoption of buprenorphine in two not-for-profit integrated health plans, over time, completing 101 semi-structured interviews with clinicians and clinician-administrators from primary and specialty care. Transcripts were reviewed, coded, and analyzed. A strong leader championing the new treatment was critical for adoption in both health plans. Once clinicians began using buprenorphine, patients' and other clinicians' experiences affected decisions more than did the champion. With experience, protocols developed to manage unsuccessful patients and changed to support maintenance rather than detoxification. Diffusion outside addiction and mental health settings was nonexistent; primary care clinicians cited scope-of-practice issues and referred patients to specialty care. With greater diffusion came questions about long-term use and safety. Recognizing how implementation processes develop may suggest where, when, and how to best expend resources to increase adoption of such treatments.",
keywords = "Buprenorphine, Diffusion of technology, Implementation research, Medication adoption, Opioid addiction, Qualitative research",
author = "Green, {Carla A.} and Dennis McCarty and Jennifer Mertens and Lynch, {Frances L.} and Anadam Hilde and Alison Firemark and Weisner, {Constance M.} and David Pating and Anderson, {Bradley M.}",
year = "2014",
month = "3",
doi = "10.1016/j.jsat.2013.09.002",
language = "English (US)",
volume = "46",
pages = "390--401",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - A qualitative study of the adoption of buprenorphine for opioid addiction treatment

AU - Green, Carla A.

AU - McCarty, Dennis

AU - Mertens, Jennifer

AU - Lynch, Frances L.

AU - Hilde, Anadam

AU - Firemark, Alison

AU - Weisner, Constance M.

AU - Pating, David

AU - Anderson, Bradley M.

PY - 2014/3

Y1 - 2014/3

N2 - Qualified physicians may prescribe buprenorphine to treat opioid dependence, but medication use remains controversial. We examined adoption of buprenorphine in two not-for-profit integrated health plans, over time, completing 101 semi-structured interviews with clinicians and clinician-administrators from primary and specialty care. Transcripts were reviewed, coded, and analyzed. A strong leader championing the new treatment was critical for adoption in both health plans. Once clinicians began using buprenorphine, patients' and other clinicians' experiences affected decisions more than did the champion. With experience, protocols developed to manage unsuccessful patients and changed to support maintenance rather than detoxification. Diffusion outside addiction and mental health settings was nonexistent; primary care clinicians cited scope-of-practice issues and referred patients to specialty care. With greater diffusion came questions about long-term use and safety. Recognizing how implementation processes develop may suggest where, when, and how to best expend resources to increase adoption of such treatments.

AB - Qualified physicians may prescribe buprenorphine to treat opioid dependence, but medication use remains controversial. We examined adoption of buprenorphine in two not-for-profit integrated health plans, over time, completing 101 semi-structured interviews with clinicians and clinician-administrators from primary and specialty care. Transcripts were reviewed, coded, and analyzed. A strong leader championing the new treatment was critical for adoption in both health plans. Once clinicians began using buprenorphine, patients' and other clinicians' experiences affected decisions more than did the champion. With experience, protocols developed to manage unsuccessful patients and changed to support maintenance rather than detoxification. Diffusion outside addiction and mental health settings was nonexistent; primary care clinicians cited scope-of-practice issues and referred patients to specialty care. With greater diffusion came questions about long-term use and safety. Recognizing how implementation processes develop may suggest where, when, and how to best expend resources to increase adoption of such treatments.

KW - Buprenorphine

KW - Diffusion of technology

KW - Implementation research

KW - Medication adoption

KW - Opioid addiction

KW - Qualitative research

UR - http://www.scopus.com/inward/record.url?scp=84892482605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892482605&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2013.09.002

DO - 10.1016/j.jsat.2013.09.002

M3 - Article

VL - 46

SP - 390

EP - 401

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 3

ER -